For these reasons, a VE-cadherin gene modified DC-based vaccine was developed and successfully tested in kidney, breast, and colon cancer models, resulting in delayed tumor progression and enhancing survival rates by the production of a large amounts of immunoglobulins, and the increase of T effector cells and cytotoxicity against VE-cadherin, as well as the reduction of immunosuppressor cells, including MDSCs (63). This evidence concerns the gene CDH5 and colonic neoplasm.